Text Size: a  |   a 

Cholesterol Lowering Drug May Be Candidate for MS and Parkinson's Treatment

January 12, 2016

A drug that treats patients with high cholesterol is being tested for its effectiveness in treating multiple sclerosis and Parkinson’s Disease. The drug is called Simvastatin and a double-blinded placebo study that will examine 198 patients with Parkinson’s Disease across the UK.

"It is encouraging to see new compounds that are already approved as being safe for use in man being trialed for use in Parkinson's," said Camille Carroll, who will help conduct the trial, in a press release. "There have been few innovations in the treatment of Parkinson's for over 40 years and for the more than 127,000 people living with the condition in the U.K., the results of this trials program could lead to new and highly effective treatments in the armory of medications to tackle Parkinson's."

As far as MS, a trail has already been done and yielded so-so results. Researchers from a 2014 study stated that a trial indicated oral statins were partially effective as a monotherapy in treatment of RRMS. When tested in combination with interferon-beta, some studies actually found an increase in clinical disease activity, relapses and new lesions in the brain. Other studies, however, have reported that the combination therapy of statin and interferon-beta had no effect on relapse rate.